hemeonclinx Medical News

Oncology

Become a Member Today!

Email
Password
Remember me
Forgot your Password?
Invite Code?

Home
General Oncology

For Practicing
Oncologists

Conferences

Jobs

Newsletters

Topics in
Oncology

Alternative Therapies

Anemia/Polycythemia

BMT/SCT

Basic Science/Genetics

Bone/Cartilage

Breast

Carcinogenesis

Coagulation/Bleeding Dz

Colorectal Cancer/Polyps

Dermatologic Oncology

Diagnostics/Radiology

Economics of Medicine

Endocrine Oncology

GI Oncology

Gynecologic Oncology

Head and Neck

Hepatobiliary/Pancreas

Leukemia/Lymphoma

Lung/Thoracic Oncology

Myeloproliferative Dz

Neurologic Oncology

Pain/Palliative Care

Pediatric Heme/Oncology

Pharmacology/Therapy

Popular Press

Renal/Urologic

Side Effects

Soft Tissue/Sarcoma

Transfusion Medicine

Help

Resource Center

RSS News Feeds

Send Newsletter
to a Friend

Sponsor

For Practicing Oncologists

Technology Advances: CISH technology Facilitates Assay of HER2 Expression
Dorothy J. Schirf, MD, MDLinx Oncology

Today's Oncology News: VEGFb Designated Orphan Drug Status By FDA
D Scott Cunningham MD, PhD, MDLinx Oncology

See all

Oncology, Hematology, cancer journals, cancer articles, oncology conference, cancer medical journals, medical news, cancer, breast cancer, cancer articles, drugs,leukemia, lymphoma, blood, articles, medical diagnosis, chemotherapy, multiple myeloma,interferon, bone marrow, hodgkin's disease, bone marrow transplant, cancer treatment, aml, cml, chronic lymphocytic leukemia, acute lymphocytic leukemia, squamous cell cancer, american society of hematology, radiation oncology, pediatric oncology, american society of clinical oncology, cancer news, prostate cancer, colon cancer, ovarian cancer, cervical cancer, neoplasm, immunosuppression, kaposi's sarcoma, malignancy, mammography, bone marrow transplantation, tamoxifen, leucovorin, 5-FU, carboplatin, stem cell, mutation, genetic, oncogenic, carcinogenic, 5 year survival, stage, progression, metastatic, radical, prostatectomy, end of life, pain control

Article Summary

Click the title below to leave the MDLinx Network and go to the Journal's Website

Prolonged Versus Standard Gemcitabine Infusion: Translation of Molecular Pharmacology to New Treatment Strategy
The Oncologist, 04/02/08

Print

Email This Article

Save in My Library

Free Full Text

Veltkamp SA et al. - We discuss the molecular pharmacology of nucleoside analogues and the influence of hNTs and dCK on the activity and toxicity of gemcitabine, which is the basis for clinical studies on FDR administration, and the results of FDR gemcitabine administration in patients. These findings might aid optimal clinical application of gemcitabine in the future.

Sponsor

Read a Different Specialty

Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT

Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology

Orthopedics
Pediatrics
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology

Profession Index

Dentist
Hospital Administrator
Nurse

Medical Students
Nurse Practitioner
Pharma/Drug Marketer

Pharmacist
Physician
Physician Assistants

Article Search

Keyword:

Search:

Published within:

Sort By:
Date Relevance

Click Here

Sponsor

Sponsor

| | | | | | |

English | Español | Français | Deutsch | 中文 | Руccкий | Norsk | Nederlands | Português | Italiano

©1999-2008 MDLinx, Inc.